Microbiology of pediatric soft tissue abscesses presenting to a Low-Middle Income Country
DOI:
https://doi.org/10.46831/jpas.v2i2.154Keywords:
Abscess, Organisms, Pediatric, Low middle-income country, SurgeryAbstract
Background: Skin and Soft Tissue Infections (SSTIs) are a prevalent and diverse group of clinical conditions, ranging from simple abscesses to severe cellulitis, often involving microbial invasion of skin and underlying soft tissues. Understanding the microbiology and antibiotic sensitivities of these infections is essential for effective management.
Methods: A retrospective cross-sectional study was conducted at The Aga Khan University Hospital in Pakistan. Data from 154 pediatric patients aged up to 17 years diagnosed with soft tissue abscesses were reviewed between January 2015 and June 2019. Exclusion criteria were applied to ensure the study's accuracy.
Results: Among the 121 included patients, the majority were male (57.9%), and children less than one year of age accounted for the highest percentage (43%). The most frequently affected anatomical sites were the legs and thighs (17.3%), followed by the buttocks (15.7%) and arms/forearms (13.2%). Staphylococcus Aureus was the most common pathogen (64.5%), with 89.7% being Methicillin-Sensitive Staphylococcus Aureus (MSSA) and 11.3% MRSA. Other pathogens included Streptococci, Escherichia coli, and anaerobic Bacteroides species.
Conclusion: MRSA remains a concern in pediatric SSTIs, necessitating targeted antibiotic therapy. However, MSSA was the primary pathogen and empirical antibiotic therapy remains crucial, guided by culture results. Improving injection safety practices is essential for reducing SSTI incidence. This study contributes valuable insights for optimizing SSTI management and underscores the need for evidence-based decisions in resource-constrained settings.
Downloads
Metrics
References
Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168(14):1585-91. doi: 10.1001/archinte.168.14.1585.
Moran GJ, Krishnadasan A, Mower WR, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: A randomized clinical trial. JAMA. 2017;317(20):2088-96. doi: 10.1001/jama.2017.5653.
Keren R, Luan X, Localio R, et al. Pediatric research in inpatient settings (PRIS) network. Prioritization of comparative effectiveness research topics in hospital pediatrics. Arch Pediatr Adolesc Med. 2012;166(12):1155–64.
Burnham JP, Kollef MH. Treatment of severe skin and soft tissue infections: a review. Curr Opin Infect Dis. 2018;31(2):113-9. doi: 10.1097/QCO.0000000000000431.
Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374(9):823-32. doi: 10.1056/NEJMoa1507476.
Jenkins TC, Knepper BC, Sabel AL, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med. 2011;171(12):1072-9. doi: 10.1001/archinternmed.2011.29.
Crisp JG, Takhar SS, Moran GJ, et al. Inability of polymerase chain reaction, pyrosequencing, and culture of infected and uninfected site skin biopsy specimens to identify the cause of cellulitis. Clin Infect Dis. 2015;61:1679–87.
McMullan BJ, Andresen D, Blyth CC, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis. 2016;16(8):e139-52. doi: 10.1016/S1473-3099(16)30024-X.
Russo A, Concia E, Cristini F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect. 2016;22 Suppl 2:S27-36. doi: 10.1016/S1198-743X(16)30095-7.
Vermandere M, Aertgeerts B, Agoritsas T, et al. Antibiotics after incision and drainage for uncomplicated skin abscesses: A clinical practice guideline. BMJ. 2018;360:k243. doi: 10.1136/bmj.k243.
Ramakrishnan K, Salinas RC, Agudelo Higuita NI. Skin and soft tissue infections. Am Fam Physician. 2015;92(6):474-83.
Duong M, Markwell S, Peter J, et al. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med. 2010;55(5):401-7. doi: 10.1016/j.annemergmed.2009.03.014.
Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med. 1985;14(1):15-9. doi: 10.1016/s0196-0644(85)80727-7.
Hogan PG, Rodriguez M, Spenner AM, et al. Impact of systemic antibiotics on staphylococcus aureus colonization and recurrent skin infection. Clin Infect Dis. 2018;66(2):191-7. doi:10.1093/cid/cix754.
Del Giudice P. Skin Infections caused by staphylococcus aureus. Acta Derm Venereol. 2020;100(9):adv00110. doi: 10.2340/00015555-3466.
Lawrence KR, Golik MV, Davidson L. The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Am J Ther. 2009;16(4):333-8. doi: 10.1097/MJT.0b013e31817fdea8.
David MZ, Daum RS. Treatment of staphylococcus aureus infections. Curr Top Microbiol Immunol. 2017;409:325-83. doi: 10.1007/82_2017_42.
Natsis NE, Cohen PR. Coagulase-negative staphylococcus skin and soft tissue infections. Am J Clin Dermatol. 2018;19(5):671-7. doi: 10.1007/s40257-018-0362-9.
Alm RA, McLaughlin RE, Kos VN, et al. Analysis of staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother. 2014;69(8):2065–75.
Berens P, Swaim L, Peterson B. Incidence of methicillin-resistant Staphylococcus aureus in postpartum breast abscesses. Breastfeed Med. 2010;5(3):113–5.
Alonzo F 3rd, Torres VJ. The bicomponent pore-forming leukocidins of Staphylococcus aureus. Microbiol Mol Biol Rev. 2014;78(2):199–230.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Saman Hamid, Kashaf Khalid, Areej Salim, Muhammad Arshad
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
